{"protocolSection":{"identificationModule":{"nctId":"NCT01220622","orgStudyIdInfo":{"id":"BSP-SOP-040"},"organization":{"fullName":"Ministry of Science and Technology of the People´s Republic of China","class":"OTHER_GOV"},"briefTitle":"Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes","officialTitle":"Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)","acronym":"NICE"},"statusModule":{"statusVerifiedDate":"2010-10","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-10"},"primaryCompletionDateStruct":{"date":"2012-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2012-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2010-10-12","studyFirstSubmitQcDate":"2010-10-13","studyFirstPostDateStruct":{"date":"2010-10-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-10-13","lastUpdatePostDateStruct":{"date":"2010-10-14","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Yongjun Wang","oldOrganization":"Beijing Tian Tan Hospital, Capital Medical University, China"},"leadSponsor":{"name":"Ministry of Science and Technology of the People´s Republic of China","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The trial was designed to test the hypothesis that early treatment with nimodipine has a positive effect on cognition impairment after acute ischemic stroke.","detailedDescription":"656 patients diagnosed with acute cerebral ischemia disease (onset≤7d) based on ICD-10 and CT/MRI criteria, who have cognitive impairment meeting all of the inclusion criteria and none of the exclusion criteria, will be included and randomized into nimodipine treatment group and the controlled group.Evaluations of cognitive function will be taken at baseline, 1 month, 3 months, and 6 months."},"conditionsModule":{"conditions":["Stroke","Mild Cognitive Impairment"],"keywords":["Stroke","Mild cognitive impairment","Nimodipine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":656,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Nimodipine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nimodipine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Nimodipine","description":"Administration of nimodipine 30mg tid for 6 months","armGroupLabels":["Nimodipine"],"otherNames":["Nimodiping Pian"]},{"type":"DRUG","name":"Placebo","description":"Administration of placebo 30mg tid for 6 months","armGroupLabels":["Placebo"],"otherNames":["Control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 6 months in the ITT population","timeFrame":"6 months"}],"secondaryOutcomes":[{"measure":"Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 6 months in the ITT population","timeFrame":"6 months"},{"measure":"The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 6 months","timeFrame":"6 months"},{"measure":"Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 3 months in the ITT population","timeFrame":"3 months"},{"measure":"Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 3 months in the ITT population","timeFrame":"3 months"},{"measure":"The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 1 month","timeFrame":"1 month"},{"measure":"The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 3 months","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1. Subjects between 30 and 80 years.\n* 2. ICD-10 and CT/MRI criteria for acute cerebral infarction.\n* 3. Stroke within 7 days after onset.\n* 4.based on years of education correction.MMSE\\>17(illiteracy),MMSE\\>20(primary school),MMSE\\>24(others)\n* 5. MoCA≤26 at baseline.\n* 6.Hachinski ischemic score ≥7 at baseline.\n* 7.Expected good compliance to study.\n* 8.Informed consent signed.\n\nExclusion Criteria:\n\n* 1.Diagnosis of schizophrenia, major anxiety syndrome, major depression.\n* 2.Alzheimer disease, Parkinson disease, Huntington disease, and fronto-temporal dementia.\n* 3.Dementia caused by (e.g., central nervous system trauma, tumor, infections, metabolic disorders, normal pressure hydrocephalus, lack of folic acid or vitamin B12, or thyroid hormone deficiency).\n* 4.Contraindications to dihydropyridine derivatives.\n* 5.Aphasia or other diseases that affect cognitive evaluation.\n* 6.Serious arrhythmias, bradycardia (\\<50 bpm) or tachycardia (\\>120 bpm); myocardial infarction within the past 6 months; blood pressure \\<90/60mmHg; severe renal or hepatic insufficiency; severe anemia, Hb\\<100g/L; severe gastrointestinal disorders; tumor.\n* 7.History of epilepsy, use of the antiepileptic drugs.\n* 8.CT/MRI showed neurodegenerative changes or other lesions except cerebral ischemia.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Feng tao, M.D.","role":"CONTACT","phone":"00861067098343","email":"happyft@sina.com"},{"name":"Wang xuemei, M.D.","role":"CONTACT","email":"minnie_wxm@hotmail.com"}],"overallOfficials":[{"name":"Wang Yongjun, M.D.","affiliation":"Beijing Tian Tan Hospital, Capital Medical University, Beijing, China","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beijing Tian Tan Hospital, Capital Medical University","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Feng tao, M.D.","role":"CONTACT","phone":"00861067098343","email":"happyft@sina.com"},{"name":"Wang xuemei, M.D.","role":"CONTACT","email":"minnie_wxm@hotmail.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000060825","term":"Cognitive Dysfunction"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000003072","term":"Cognition Disorders"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M29395","name":"Cognitive Dysfunction","asFound":"Mild Cognitive Impairment","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M5991","name":"Cognition Disorders","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000009553","term":"Nimodipine"}],"ancestors":[{"id":"D000000959","term":"Antihypertensive Agents"},{"id":"D000002121","term":"Calcium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000077264","term":"Calcium-Regulating Hormones and Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000014665","term":"Vasodilator Agents"}],"browseLeaves":[{"id":"M12182","name":"Nimodipine","asFound":"Autoinjector","relevance":"HIGH"},{"id":"M3967","name":"Antihypertensive Agents","relevance":"LOW"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M5074","name":"Calcium Channel Blockers","relevance":"LOW"},{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"}]}},"hasResults":false}